Nexsen Limited (ASX:NXN): Clinical trial launch positions StrepSure® as a potential standard in maternal diagnostics

Nexsen Limited (ASX:NXN) has reached a pivotal milestone with the commencement of its first clinical trial for the Group B Streptococcus (GBS) Rapid Sensor, to be marketed as StrepSure®.

The trial, conducted in partnership with RMIT University and led by Professor Lisa Hui at Northern Hospital in Victoria, marks the clinical validation phase of the company’s next-generation nano-biotechnology platform.

Highlights

• Clinical trial underway at Northern Hospital, Epping, enrolling expectant mothers during labour.

• Overseen by Professor Lisa Hui, a leading authority in maternal-fetal medicine.

• Trial registered with ANZCTR and approved by the Royal Children’s Hospital Melbourne Human Research Ethics Committee.

• Initial 1,000 investigational StrepSure® devices manufactured under ISO 13485 standards.

• Potential early market penetration as soon as the second half of CY2026, with international markets under review.

Nexsen’s diagnostic innovation targets a long-standing challenge in maternal care, Group B Streptococcus, a bacterium found in up to 20 percent of pregnant women, can cause life-threatening infections in newborns if undetected during labour.

Conventional pathology-based testing can take days and is typically performed weeks before birth, leaving clinicians without real-time results when it matters most.

By contrast, Nexsen’s StrepSure® aims to provide accurate, point-of-care results during labour, allowing healthcare professionals to make immediate, informed decisions on antibiotic use and clinical management.

The technology employs ultra-bright nanoparticles and high-affinity bioreceptors within a modular lateral flow system, combining laboratory-grade precision with rapid turnaround times at the bedside.

Managing Director Mark Muzzin said the commencement of the clinical trial represents both validation and acceleration of the company’s broader commercial pathway.

“The successful completion of this trial will validate Nexsen’s commercialisation strategy for the GBS Rapid Sensor, which will be marketed as StrepSure® upon launch. We are advancing our regulatory pathway, scaled production planning and global commercial rollout of our flagship diagnostic technology,”  he said.

Professor Hui, principal investigator for the trial, underscored the clinical significance of the work, noting that the sensor’s point-of-care design could help optimise antibiotic use, reduce hospital stays, and improve national healthcare efficiency.

The company’s approach combines scientific innovation with practical integration into clinical workflows. Devices have been specifically designed for use in busy maternity wards, with user feedback incorporated into the engineering phase.

Early operational feedback from Northern Health indicates the system is adaptable to existing labour ward procedures, supporting smooth adoption once regulatory clearance is achieved.

From a broader perspective, Nexsen’s initiative sits within a growing global movement toward decentralised diagnostics.

Rapid, accessible testing tools are reshaping how infectious diseases and maternal health risks are managed, particularly in settings where laboratory access is limited.

With 132 million births globally each year and an estimated one in five expectant mothers carrying GBS, the potential scale for point-of-care screening is substantial.

The trial outcome will be closely watched by both the medical community and diagnostic industry stakeholders.

Successful validation could enable Nexsen to advance regulatory submissions, including potential engagement with the US Food and Drug Administration, while establishing the foundations for international distribution.

Nexsen’s transition from research to real-world clinical testing signals a defining moment in the maturation of its biosensor platform.

The StrepSure® trial not only tests a product but also demonstrates how Australian-developed nanotechnology can address global healthcare inefficiencies.

As the data emerges, Nexsen’s progress may help redefine how maternal diagnostics are delivered, transforming what was once a laboratory procedure into an immediate, point-of-care decision tool for clinicians worldwide.